|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Cash flows from operating activities | |
| Income (loss) for the year | |
| Adjustments for: | |
| Depletion and depreciation | |
| Impairment charge (Note 9) | |
| Share-based compensation expense (Note 14) | |
| Share of profit of associates (Note 9) | |
| Loss (gain) on revaluation of financial instruments | |
| Interest and finance expenses (Note 12) | |
| Tax expense (Note 13) | |
| Other non-cash movements (Note 22) | |
| Accounts receivable | |
| Accounts payable and accrued liabilities | |
| Total cash provided by operating activities before taxes | |
| Taxes paid | |
| Total cash provided by operating activities | |
| Cash flows from investing activities | |
| Distributions from SLM California (Note 9) | |
| Acquisition of royalty interests (Note 8) | |
| Net cash received from the purchase of EMX Royalty Corp. (Note 4) | |
| Proceeds from royalty buy-back (Note 8) | |
| Proceeds from the sale of investments | |
| Purchase of Tether Gold cryptocurrency tokens (Note 7) | |
| Other movements (Note 22) | |
| Total cash provided by (used in) investing activities | |
| Cash flows from financing activities | |
| Interest received | |
| Interest paid | |
| Loan repayments (Note 12) | |
| Proceeds from private placement (Note 13 and 18) | |
| Share issue costs | |
| Proceeds from exercise of options and settlement of PSUs (Note 14) | |
| Finance lease payments | |
| Total cash provided by (used in) financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | |
| Change in cash and cash equivalents | |
| Cash and cash equivalents, beginning | |
| Cash and cash equivalents, ending |
Loading...
